CD19 and neoplasm: Although, in terms of in vitro or in vivo anti-tumor activity, we could not detect significant differences with EF1α-driven CAR-T cells against the CD19+ lymphoma model, AW-CAR-T cells exhibited lower tonic signaling and a less differentiated phenotype after efficient killing of CD19+ cells, with reduced secretion of pro-inflammatory cytokines.